1. Home
  2. NMCO vs ALLO Comparison

NMCO vs ALLO Comparison

Compare NMCO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Credit Opportunities Fund

NMCO

Nuveen Municipal Credit Opportunities Fund

HOLD

Current Price

$10.68

Market Cap

560.1M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.27

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMCO
ALLO
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
560.1M
539.4M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
NMCO
ALLO
Price
$10.68
$2.27
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$8.36
AVG Volume (30 Days)
126.0K
4.4M
Earning Date
01-01-0001
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$141,204.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.69
$0.86
52 Week High
$11.20
$2.80

Technical Indicators

Market Signals
Indicator
NMCO
ALLO
Relative Strength Index (RSI) 48.17 50.79
Support Level $10.68 $2.20
Resistance Level $10.74 $2.80
Average True Range (ATR) 0.11 0.18
MACD -0.02 -0.05
Stochastic Oscillator 41.86 16.67

Price Performance

Historical Comparison
NMCO
ALLO

About NMCO Nuveen Municipal Credit Opportunities Fund

Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: